R&D News | pharmaphorum

News

Novo Nordisk has claimed a key win in its head-to-head race with Agios to bring an oral PKR activator to the market for sickle cell disease.

News

The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.

News

Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.

News

AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.

News

UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.

News

When Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge – and that expectation has now been fulfilled.